Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy ...Middle East

Hanmi unveils tiral in progress poster on BH3120 at the Society for Immunotherapy of Cancer (SITC) in the U.S. Phase 1 trial is progressing smoothly, with no dose-limiting toxicity observed Phase 1 trial evaluating the combination of BH3120 and MSD's anti-PD-1 therapy, KEYTRUDA®...

Read More Details
Finally We wish PressBee provided you with enough information of ( Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy )

Also on site :

• Brynn Whitfield Announces Exit From 'RHONY' After Two Seasons
• Pop Princess Covers Classic ‘70s Rock Hit: ‘This Is So Good’
• Born on One of These 4 Dates? You're a Wise, Old Soul